comparemela.com

Latest Breaking News On - சிறுநீரகம் நோயியல் சமூகம் - Page 1 : comparemela.com

Pathline Expands Medical Team, Appoints Three New Physicians

Press release content from Business Wire. The AP news staff was not involved in its creation. Pathline Expands Medical Team, Appoints Three New Physicians May 3, 2021 GMT RAMSEY, N.J. (BUSINESS WIRE) May 3, 2021 Pathline, a leading provider of specialized anatomic pathology services, has expanded its team with a new Chief Medical Officer, Director of Hematopathology and Molecular Pathology and Senior Pathologist. The recently appointed physicians include: Gregory S. Henderson, M.D., Ph.D., F.C.A.P., F.A.S.C.P. - Chief Medical Officer Bevan Tandon, M.D. - Director of Hematopathology and Molecular Pathology Douglas Charney, M.D. - Senior Pathologist

FDA approves GSK s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US

FDA approves GSK s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US Approval builds on nearly 10 years of experience in lupus News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/  GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE), the most common form of lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant. The approval extends the current indication in the US to include both SLE and LN for both the intravenous and subcutaneous formulations.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.